Gonapeptyl (Triptorelin Acetate)

Gonapeptyl is indicated for several hormone‑dependent conditions where suppression of gonadal steroid production is required.

• Management of advanced or metastatic prostate cancer by reducing testosterone levels.
• Treatment of endometriosis to induce a hypo‑estrogenic state and relieve pelvic pain.
• Reduction of uterine fibroid size and associated bleeding through hormonal suppression.
• Control of central precocious puberty by halting premature activation of the hypothalamic‑pituitary‑gonadal axis.
• Adjunct in assisted reproductive technology to prevent premature luteinizing hormone surge during controlled ovarian stimulation.
• Used in combination with other hormonal agents for specific gynecologic protocols requiring temporary estrogen suppression.

The safety profile of Gonapeptyl reflects the pharmacologic action of GnRH agonists; side effects are related to reduced sex hormone levels and the initial stimulation phase.

Common

• Hot flashes, sweating, or night sweats.
• Decreased libido or erectile dysfunction in men; reduced sexual desire in women.
• Headache or mild dizziness.
• Injection site reactions such as redness, swelling, or pain.

Serious

• Severe allergic reaction (anaphylaxis) with rash, swelling, or breathing difficulty.
• Cardiovascular events including hypertension, arrhythmia, or myocardial infarction.
• Bone mineral density loss leading to osteoporosis with long‑term use.

Before initiating Gonapeptyl, clinicians should evaluate patient history and consider specific warnings to minimize risks.

• Assess cardiovascular status; use cautiously in patients with hypertension, coronary artery disease, or recent myocardial infarction.
• Evaluate bone health; prolonged therapy may increase risk of osteoporosis or fractures.
• Screen for hormone‑dependent tumors; avoid use in active breast or ovarian cancer.
• Monitor liver function; rare cases of hepatic dysfunction have been reported.
• Consider potential flare effect; initial GnRH agonist stimulation can transiently increase hormone levels.
• Use only under specialist supervision during pregnancy planning, as fetal exposure effects are unknown.

Gonapeptyl can alter the metabolism or effectiveness of several concomitant medications; awareness of interactions helps maintain therapeutic outcomes.

Avoid

• Concomitant use with other GnRH agonists or antagonists, which may cause excessive hormone suppression.
• Strong estrogen‑containing hormonal therapies, as they counteract the intended hypo‑estrogenic effect.

Use with caution

• Anticoagulants, because injection site bleeding may be prolonged.
• Antidiabetic agents, since hormonal changes can affect glucose control.
• Corticosteroids, which may exacerbate bone loss during prolonged GnRH agonist therapy.
• Thyroid hormone replacement, as GnRH agonists can influence thyroid‑binding globulin levels.